Schedule
| Lectures: | Monday/Wednesday 10:30 A.M. - 11:20 A.M. Room: T-359 Friday 10:30 A.M. - 12:20 P.M. Room: T-359 |
| Week | Date | Topic | Faculty | Downloads |
|---|---|---|---|---|
| Week 1 | 3/26 - 3/30 | Introduction to the Nervous system and Synaptic Transmission Modulation of receptor action – barbiturates, benzodiazepines In class discussion of Science 290:13, Nature 401:796, Nature 451:330, Journal of Neuroscience 31:870-877 | Bajjalieh | Printable Schedule Slides Slides |
| Week 2 | 4/2 - 4/6 | Modulation of Excitability: Ion Channels and GABA Receptors | Catterall | |
| 4/2 | Local anesthesia and sodium channels
Molecular Basis of Neuropharmacology, Chapter 3, review pp. 33-44, read pp. 44-57. | Slides, Article, Review | ||
| 4/4 | General anesthesia, GABA receptors, and other anesthetic targets
Molecular Basis of Neuropharmacology, Chapter 7, pp. 154-163; Brenner, Pharmacology, Chapter 25. | Slides, Article | ||
| 4/6 | Epilepsy and anti-epileptic drugs; inherited epilepsies
Molecular Basis of Neuropharmacology, Chapter 21, pp. 490-502, plus papers to be assigned. | Slides, Article | ||
| Week 3 | 4/9 - 4/13 | Modulation of Neurotransmission by amines and neuropeptides | Phillips | |
| 4/9 | Neuromodulation. Introduction to the amines.
Molecular Basis of Neuropharmacology pp167-187, 192-199. |
|||
| 4/11 | Parkinson's Disease. Antidepressants
Molecular Basis of Neuropharmacology pp303-308, 312-319, 338-350. |
|||
| 4/13 | Psychostimulants, Hallucinogens, Antipyschotics
Molecular Basis of Neuropharmacology pp355-362, 383-395, 398-407; In class discussion of Beaulieu JM et al (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-73. Beaulieu JM et al (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-36. Masri B et al (2008) Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A 105:13656-61. |
|||
| Week 4 | 4/16 - 4/20 | Modulation of Neurotransmission by Therapeutic Drugs | Chavkin | |
| 4/16 | Analgesics and Pain Circuits
Reading: Chapter 19 "Pain" | Slides | ||
| 4/18 | Opioid Mechanisms
Readings: Goodman & Gilman's Pharmacological Basis of Therapeutics (11th edition) Chapter 21, pp 547-557 | Slides, Paper | ||
| 4/20 | Ligand-directed Signaling
Readings: Evans et al (2010) Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol. 159:1022-38. & Melief et al. (2010) Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A. 107:11608-13. | |||
| Week 5 | 4/23 - 4/27 | Neurodegeneration | Gardner | |
| 4/23 | The protein conformation basis of neurodegenerative diseases
Neurodegenerative Diseases: New Concepts of Pathogenesis and Their Therapeutic Implications. Skovronsky et al. 2006. Annual Review of Pathology: Mechanisms of Disease 1:151-170. Role of Axonal Transport in Neurodegenerative Diseases. De Vos et al. 2008. Annual Review of Neuroscience 31:151-173. | |||
| 4/25 | Therapeutic strategies for protein conformation diseases
How a Cell Deals with Abnormal Proteins: Pathogenetic Mechanisms in Protein Aggregation Diseases. Aigelsreiter et al. 2007. Pathobiology 74:145-158. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Rochet. 2007. Expert Reviews in Molecular Medicine 9:1-34. | |||
| 4/27 | In Class Final Exam | |||